Advertisement
Canada markets close in 4 hours 9 minutes

  • S&P/TSX

    21,797.88
    -75.84 (-0.35%)
     

  • S&P 500

    5,011.38
    -60.25 (-1.19%)
     

  • DOW

    37,858.09
    -602.83 (-1.57%)
     

  • CAD/USD

    0.7301
    +0.0003 (+0.05%)
     

  • CRUDE OIL

    82.41
    -0.40 (-0.48%)
     

  • Bitcoin CAD

    87,476.53
    -1,173.64 (-1.32%)
     

  • CMC Crypto 200

    1,377.13
    -5.45 (-0.39%)
     

  • GOLD FUTURES

    2,343.80
    +5.40 (+0.23%)
     

  • RUSSELL 2000

    1,966.12
    -29.31 (-1.47%)
     

  • 10-Yr Bond

    4.7020
    +0.0500 (+1.07%)
     

  • NASDAQ

    15,450.73
    -262.02 (-1.67%)
     

  • VOLATILITY

    16.79
    +0.82 (+5.14%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6808
    -0.0011 (-0.16%)
     
BREAKING:

HONDA TO SET UP $15B EV PRODUCTION BASE IN CANADA

Automaker to get up to $5B in government assistance for EV battery, assembly plants

Why Ionis Pharmaceuticals Stock Is Down 13% This Week

Cory Renauer, The Motley Fool
·1 min read
Why Ionis Pharmaceuticals Stock Is Down 13% This Week

Shares of Ionis Pharmaceuticals (NASDAQ: IONS), a biotechnology company, have fallen around 13.6% since their closing price on Friday, Oct. 15, 2021. Investors were disappointed by phase 3 clinical trial results for tofersen, an experimental treatment for amyotrophic lateral sclerosis. Treatment with tofersen was supposed to help reduce physical symptoms of ALS, a progressive neurodegenerative disorder that affects around 20,000 new U.S. patients annually.

Continue reading